Obulytix SRL
4.3 FTEObulytix reported total assets of €5.29m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jun 2026), with 4.3 full-time equivalents.
The score of Obulytix shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Obulytix's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jun 2026
- Year ended 31 Dec 2024filed on 02 Jul 2025
Obulytix's financial analysis
- Solvency41.9%sector median: 50.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Obulytix
Obulytix's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0803.351.624
- VAT number
- BE0803351624
- Peppol
- Registered · 0208:0803351624 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Jun 2023
- Registered office
- 9052 Ghent
- Size
- Micro · 4.3 FTE
- Latest accounts
- 2025 · filed on 22 Jun 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Obulytix (SRL) has been based in Ghent since 2023, active in: manufacture of medicaments. For 2025, it reports a net loss of €2.66m and equity of €2.22m; its revenue is not published. With 4.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 41.9%, below the median of its sector (50.3%).
Companies similar to Obulytix
Companies in the same business, of comparable size and area, outside its group.
- Minoryx Therapeutics BE Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.87m
- Orotech Manufacture of pharmaceutical preparations Temse · balance sheet €1.21m
- Cryotherapeutics Manufacture of pharmaceutical preparations Ans · balance sheet €21.8m
- invoX Belgium Manufacture of pharmaceutical preparations Diepenbeek · balance sheet €29.2m
- Indigo Diabetes Manufacture of medical and dental instruments and supplies Ghent · balance sheet €5.01m
- MSI-Dfat EU Research and experimental development on natural sciences and engineering Jodoigne · balance sheet €1.08m
- Clinical Projects International Research and experimental development on natural sciences and engineering Niel · balance sheet €5.13m
- Euro-Multitel Research and experimental development on natural sciences and engineering Mons · balance sheet €5.04m
Frequently asked questions about Obulytix
What is the revenue of Obulytix?
Obulytix files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Obulytix?
In Belgium, the VAT number is the company number prefixed with BE: BE0803351624 for Obulytix, if the company is VAT-registered. Its company number (CBE) is 0803.351.624.
Where is the registered office of Obulytix?
According to the CBE register, the registered office of Obulytix is in 9052 Ghent.
What is the equity of Obulytix?
At the close of the 2025 financial year, the equity of Obulytix amounts to 2,217,512 €, a solvency of 41.9% of total assets.
How many people work at Obulytix?
4.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Obulytix?
The register lists 10 active mandates at Obulytix. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Obulytix
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →